Well, theranostics is a very hot topic in oncology and there is a lot of drug development happening in the theranostics space. While there is a lot of excitement about alpha PRRT, which is crowding the space, we have a lot of safety and comfort with the existing beta PRRT agent like lutetium 177-dotatate. So my personal research endeavors are focusing on building on the success of lutetium 177-dotatate and adding scientifically sound radiation sensitizers to boost the efficacy without jeopardizing the safety...
Well, theranostics is a very hot topic in oncology and there is a lot of drug development happening in the theranostics space. While there is a lot of excitement about alpha PRRT, which is crowding the space, we have a lot of safety and comfort with the existing beta PRRT agent like lutetium 177-dotatate. So my personal research endeavors are focusing on building on the success of lutetium 177-dotatate and adding scientifically sound radiation sensitizers to boost the efficacy without jeopardizing the safety. So those are our goals. And what I foresee in the near future, there is a big room to incorporate these PRRT combination studies, not just in NETs, you know, as these theranostics agents kind of spread their swing and up when prostate cancer is a big, big indication and several other tumor types, we are investigating radiopharmaceutical drugs. I think the addition of smart radio sensitizers, which don’t affect the safety profile, but significantly boost the potential efficacy, I think will be the next wave of theranostic studies. So I foresee both in de novo patients where there is a role for PRRT and as well as in re-treatment patients where patients have previously progressed on PRRT and now need to be re-challenged with PRRT. I think there’s a role for combination studies and radiosensitizers in that space.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
